145 related articles for article (PubMed ID: 16515308)
1. [Optimized compliance].
Krankenpfl J; 2005; 43(7-10):238. PubMed ID: 16515308
[No Abstract] [Full Text] [Related]
2. Early interferon beta treatment in multiple sclerosis: nursing care implications of the BENEFIT study.
Webb UH
J Neurosci Nurs; 2008 Dec; 40(6):356-61. PubMed ID: 19170303
[TBL] [Abstract][Full Text] [Related]
3. [The nurse's role in multiple sclerosis treatment adherence].
Morillas-Merienne MJ; Karine P; Prouteau P; Vrillet I
Soins; 2006 Oct; (709):24-9. PubMed ID: 17111862
[No Abstract] [Full Text] [Related]
4. [Global adherence project to disease-modifying therapies in patients with relapsing multiple sclerosis: 2-year interim results].
Arroyo E; Grau C; Ramo C; Parra J; Sánchez-Soliño O;
Neurologia; 2010 Sep; 25(7):435-42. PubMed ID: 20964990
[TBL] [Abstract][Full Text] [Related]
5. Landmark papers in multiple sclerosis.
Cross AH
Neurology; 2001 Dec; 57(12 Suppl 5):S1-2. PubMed ID: 11902588
[No Abstract] [Full Text] [Related]
6. A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis.
Goodin DS
Neurology; 2006 Oct; 67(7):1313-4. PubMed ID: 17030783
[No Abstract] [Full Text] [Related]
7. Interferon-beta treatment and the natural history of relapsing-remitting multiple sclerosis.
Koch M; Mostert J; De Keyser J; Tremlett H; Filippini G
Ann Neurol; 2008 Jan; 63(1):125-6; author reply 126-7. PubMed ID: 17702024
[No Abstract] [Full Text] [Related]
8. A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis.
Durelli L; Barbero P; Clerico M;
Neurology; 2006 Dec; 67(12):2264; author reply 2264-5. PubMed ID: 17190964
[No Abstract] [Full Text] [Related]
9. Improving the convenience of home-based interferon beta-1a therapy for multiple sclerosis.
Lesaux J; Jadbäck G; Harraghy CE
J Neurosci Nurs; 1999 Jun; 31(3):174-9. PubMed ID: 10846648
[TBL] [Abstract][Full Text] [Related]
10. Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: the CoSa study.
Lugaresi A; Durastanti V; Gasperini C; Lai M; Pozzilli C; Orefice G; Sotgiu S; Pucci E; Ardito B; Millefiorini E;
Clin Neuropharmacol; 2008; 31(3):167-72. PubMed ID: 18520983
[TBL] [Abstract][Full Text] [Related]
11. [Management of the patient with multiple sclerosis].
Hébel A
Rev Infirm; 2004 Jan; (97):33-4. PubMed ID: 15027142
[No Abstract] [Full Text] [Related]
12. Benefits of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis.
Johnson KP; Due DL
Expert Rev Pharmacoecon Outcomes Res; 2009 Jun; 9(3):205-14. PubMed ID: 19527092
[TBL] [Abstract][Full Text] [Related]
13. [Ensuring the long-term effectiveness of MS treatment].
Krankenpfl J; 2005; 43(7-10):235. PubMed ID: 16515305
[No Abstract] [Full Text] [Related]
14. Long-term follow-up of the original interferon-beta1b trial in multiple sclerosis: design and lessons from a 16-year observational study.
Ebers GC; Reder AT; Traboulsee A; Li D; Langdon D; Goodin DS; Wolf C; Beckmann K; Konieczny A;
Clin Ther; 2009 Aug; 31(8):1724-36. PubMed ID: 19808131
[TBL] [Abstract][Full Text] [Related]
15. [Clinical importance of neutralising antibodies against interferon-beta in patients with relapsing-remitting multiple sclerosis].
Sørensen S; Koch-Henriksen NJ; Pedersen CR; Clemmesen KM; Bendtzen K; Frederiksen JL; Jensen K; Kristensen O; Petersen T; Rasmussen S; Ravnborg M; Stenager E;
Ugeskr Laeger; 2004 Oct; 166(41):3606-9. PubMed ID: 15515467
[No Abstract] [Full Text] [Related]
16. Interferon-beta1b in multiple sclerosis: effect on progression of disability and clinical markers of treatment response.
Carmona O; Casado V; Moral E; Alonso-Magdalena L; Martínez-Yélamos A; Martínez-Yélamos S; Martín-Ozaeta G; Arbizu T
Eur Neurol; 2008; 60(6):279-84. PubMed ID: 18824855
[TBL] [Abstract][Full Text] [Related]
17. The best clinical paper on multiple sclerosis in 2012: commentary.
Hutchinson M
Mult Scler; 2013 Apr; 19(5):522-3. PubMed ID: 23599183
[No Abstract] [Full Text] [Related]
18. Putting MS patients back in control. Interview by Nicola O'Connell.
Gutteridge V
Nurs Times; 2006 Aug 15-21; 102(33):20-1. PubMed ID: 16937732
[No Abstract] [Full Text] [Related]
19. Interferons in relapsing remitting multiple sclerosis.
Rudick RA; Cookfair DL; Griffin J; Hauser S; Piantadosi S
Lancet; 2003 May; 361(9371):1824; author reply 1824-5. PubMed ID: 12781561
[No Abstract] [Full Text] [Related]
20. Interferons in relapsing remitting multiple sclerosis.
Freedman M; King J; Oger J; Sharief M; Hartung HP;
Lancet; 2003 May; 361(9371):1822-3; author reply 1823-4. PubMed ID: 12781558
[No Abstract] [Full Text] [Related]
[Next] [New Search]
